Established Investigator Awards
The MRA Established Investigator Awards support senior researchers conducting impactful translational research to improve melanoma prevention, diagnosis, staging, and treatment.
Funder: Melanoma Research Alliance
Due Dates (Anticipated): September 2026: Letter of Intent | September 2026: Eligibility checklist & biosketch (Young Investigator) | November 2026: Full proposal (Young Investigator and Pilot Awards) | January 2027: Invited Team Science full proposal | October 2026: RTFCCR-MRA Special Opportunity LOI | February 2027: RTFCCR-MRA Special Opportunity invited full application
Funding Amounts: MRA expects to support at least $11.5 million in new funding across all mechanisms in the cycle; typical Established Investigator Awards are up to $125,000/year for 3 years (total $375,000).
Summary: Supports senior investigators with a proven track record to advance impactful translational research in melanoma prevention, diagnosis, staging, and treatment.
Key Information: All deadlines are projected; confirm on the program page when the new RFP is released.
Description
The Established Investigator Awards from the Melanoma Research Alliance (MRA) are designed to support senior researchers who have demonstrated significant scientific productivity and are beyond the initial five years of their first academic faculty appointment. These awards fund high-impact, translational research projects that align with MRA’s mission to improve the prevention, diagnosis, staging, and treatment of melanoma. The program seeks to accelerate advances that will make a substantial difference in patient outcomes in the near and intermediate future.
